Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2007
08/16/2007US20070191359 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof
08/16/2007US20070191358 Novel piperidine derivative for the treatment of depression
08/16/2007US20070191357 Methods of using potassium channel inhibiting compounds
08/16/2007US20070191356 Pyridobenzoxazine derivative
08/16/2007US20070191355 8-[2-(4-Acetylpiperazin-1-yl)ethyl]-8-azabicyclo[3.2.1]octan-3-one; useful for the preparation of gastrointestinal moltility drugs, indazolecarboxamide-8-azabicyclo-[3.2.1]octane and quinolinonecarboxamide-8-azabicyclo[3.2.1]octane derivatives
08/16/2007US20070191354 10th Carbon substitution with nitrogen heterocyclic group, halogen, or cycloalkyl or aryl group for use as stable agents against Plasmodium falciparum, Neospora caninum and Eimeria tenella which cause malaria, neosporosis and coccidiosis; 10 beta -phenyl-10-deoxo-10-dihydroartemisinin
08/16/2007US20070191353 Use of thiadiazoleurea derivatives
08/16/2007US20070191352 Prophylaxis, therapy of Alzheimer's disease, Pick's disease; administering phenothiazine compound such as methylene blue
08/16/2007US20070191351 Salts of potassium atp channel openers and uses thereof
08/16/2007US20070191350 Combinations comprising alpha-2-delta ligands
08/16/2007US20070191349 C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases
08/16/2007US20070191348 Isopropanol water solvate of olanzapine
08/16/2007US20070191347 Substituted sulfonamides and ureas useful for inhibiting kinase activity
08/16/2007US20070191346 3-Cyano-quinoline derivatives
08/16/2007US20070191345 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders
08/16/2007US20070191344 Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
08/16/2007US20070191343 4-((4-(2-Azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewith
08/16/2007US20070191342 Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof
08/16/2007US20070191341 N-Substituted Benzene Sulfonamides
08/16/2007US20070191340 Compounds Which Modulate The CB2 Receptor
08/16/2007US20070191339 Crystalline forms of a pharmaceutical compound
08/16/2007US20070191338 Combinations comprising staurosporines
08/16/2007US20070191337 Annellated carbamyl-aza-heterocyclic compounds, a focused library, pharmaceutical compositions, and methods of preparing the same
08/16/2007US20070191336 p38 kinase inhibitors
08/16/2007US20070191335 Heterocylic antiviral compounds
08/16/2007US20070191334 Tricyclic imidazopyridines
08/16/2007US20070191333 Antibacterial agents
08/16/2007US20070191332 Compounds for the treatment of inflammatory disorders
08/16/2007US20070191331 Crystalline forms of cefdinir potassium salt
08/16/2007US20070191330 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
08/16/2007US20070191329 Ethylene glycol esters as photoactive agents
08/16/2007US20070191328 Isoquinoline compounds
08/16/2007US20070191327 Sterilization of corticosteroids with reduced mass loss
08/16/2007US20070191326 Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
08/16/2007US20070191325 Methods for altering insulin secretion
08/16/2007US20070191324 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
08/16/2007US20070191323 Stable corticosteroid mixtures
08/16/2007US20070191322 Cationic Steroid Microbial Compositions and Methods of Use
08/16/2007US20070191321 Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
08/16/2007US20070191320 Methods of treatment for female sexual arousal disorder
08/16/2007US20070191319 Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
08/16/2007US20070191318 Process for the preparation of amorphous rosuvastatin calcium
08/16/2007US20070191317 (20R,25R)-2-Methylene-19,26-dinor-1 alpha ,25-dihydroxyvitamin D3, used for the treatment of psoriasis, leukemia, cancer, multiple sclerosis, lupus, diabetes, graft versus host disease, transplant rejection, inflammatory diseases, skin disorders, osteoporosis and rickets
08/16/2007US20070191316 2-Methylene-19,26-dinor-1 alpha ,25-dihydroxyvitamin D3; psoriasis; leukemia, cancer, multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; decrease the calcemic effect while retaining the ability to suppress parathyroid hormone
08/16/2007US20070191315 Method for administering ibandronate
08/16/2007US20070191314 Thermoreversible Oil-In-Water Emulsion
08/16/2007US20070191313 1-Benzyl-5-hydroxy-2-methyl-1H-indole-3-carboxylic Acid, 3,5-Difluorobenzylamide, useful for treating vision defects, angiogenesis, cardiovascular disorders and as wound healing agents
08/16/2007US20070191312 Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as beta-lactamase inhibitors and antibacterials
08/16/2007US20070191311 P2x receptor inhibitor
08/16/2007US20070191310 Antiinflammatory agents; antiischemic agents; antiarthritic agents; antihistamines; multiple sclerosis; Alzheimer's disease; Huntington's disease; parkinson's disease; antiepileptic agents; 1-Stearoyl-2-{3-[2-(2,6-dichloroanilino)phenylacetamido]propanoyl}-sn-glycero-3-phosphocholine
08/16/2007US20070191309 a 7 or 8-hydroxy; a protected oxygen at position 11; carbamate protecting group at the N10 position (oxycarbonyl); reaction with a diiodoalkane; antitumour anthramycin antibiotic
08/16/2007US20070191308 Intranasal formulation of rotigotine
08/16/2007US20070191307 complexation of cyclodextrin with carotenoids and incorporation of the complexes into the nutritional supplements without intermediate collection, isolation, and drying steps; for enhanced absorption of nutritional agents; bioavailability
08/16/2007US20070191306 FACTOR Xa INHIBITOR FORMULATION AND METHOD
08/16/2007US20070191305 Chromone complexes
08/16/2007US20070191304 Methods for performing percutaneous coronary intervention
08/16/2007US20070191303 Polysaccharide compositions and methods of producing, screening, and formulating polysaccharide compositions
08/16/2007US20070191302 e.g. 4-[4-(hydroxybenzoylamino)benzoylamino]butanoic acid; antithrombotic, antiinflammatory, anticarcinogenic agent, antiallergen; mixture with heparin or glycosaminoglycan oligosaccharides; increase the oral absorption of heparin
08/16/2007US20070191301 for reducing animal core temperatures and rate of oxygen consumption; protecting against myocardial damage during cardioplegia; cardiovascular disease, neurological disorders, ophthalmic conditions, ischemic conditions, reperfusion injury, obesity, wasting disease, and/or diabetes
08/16/2007US20070191299 Extension Of The Expression of Transgenic Proteins By Immunomodulation
08/16/2007US20070191294 Short interfering rna (sirna) analogues
08/16/2007US20070191293 Inhibitors of E1 activating enzymes
08/16/2007US20070191291 Compound antibacterial drugs comprising n-acetyl-d-glucosamine
08/16/2007US20070191290 Treatment of Alzheimer's disease (AD) and senile dementia of the Alzheimer's type (SDAT); administering dose of sarsasapogenin
08/16/2007US20070191289 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
08/16/2007US20070191288 Treatments for Benign Tumors, Cancers, Neoplasias, and/or Other Inflammatory Disorders or Diseases
08/16/2007US20070191287 D-ribose for improving depression-like symptoms
08/16/2007US20070191286 Injectable composition
08/16/2007US20070191281 Compound containing a labile disulfide bond
08/16/2007US20070191279 Administering adenosine A1 receptor antagonist 1,3-dipropyl-8-(2-(5,6-epoxy)norbornyl)xanthine(CVT-124) for modulating osteoclastogenesis and for treating bone diseases characterized by bone loss or a decrease in bone mass or density
08/16/2007US20070191274 Active hedgehog protein conjugate
08/16/2007US20070191268 Recombiant lubricin molecules and uses thereof
08/16/2007US20070191267 Use of tyrosine kinase inhibitors for treating cerebral ischemia
08/16/2007US20070191263 Valency platform molecules comprising aminooxy groups
08/16/2007US20070191260 Novel indole derivative for alkylating specific base sequence of dna and alkylating agent and drug containing the derivative
08/16/2007US20070190652 Anti-HIV Agent
08/16/2007US20070190567 Treatment for asthma and allergy
08/16/2007US20070190561 Nucleotide sequences coding polymerase for use in identifying modulators to treat cell proliferative disorders; enzyme inhibitors; antitumor agents
08/16/2007US20070190550 Novel compositions and methods for the identification, assessment, prevention, and therapy of human cancers
08/16/2007US20070190523 Method and compositions for identifying anti-hiv therapeutic compounds
08/16/2007US20070190192 Novel abietane diterpenoid compound, and composition comprising extract of torreya nucifera, or abietane diterpenoid compounds or terpenoid compounds isolated from them for prevention and treatment of cardiovascular disease
08/16/2007US20070190191 Use of geraniol in antitumoral therapy
08/16/2007US20070190190 Conditioning compositions and methods of use thereof
08/16/2007US20070190188 Controlling Toxicity of Aminoquinoline Compounds
08/16/2007US20070190187 Formulation for enhanced delivery of phenethylamine
08/16/2007US20070190185 Plant extract mixtures and their uses
08/16/2007US20070190182 Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
08/16/2007US20070190181 Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
08/16/2007US20070190180 Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
08/16/2007US20070190178 Composition and method for the therapeutic modulation of matrix metalloproteinase
08/16/2007US20070190177 Zinc composition and their use in anti-microbial applications
08/16/2007US20070190176 Antimicrobial composition
08/16/2007US20070190172 Enhanced activity biocidal hydrogen peroxide composition
08/16/2007US20070190164 therapeutic amount of ecteinascidin 743 is administered in combination with a prodrug capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine as anticarcinogenic agent; antimetastasis agent
08/16/2007US20070190161 Solid formulation for dialysis and process for producing the same
08/16/2007US20070190158 Pharmaceutical compositions in particulate form
08/16/2007US20070190156 Ion channel modulating compounds and uses thereof
08/16/2007US20070190153 Delivery systems for non-steroidal anti-inflammatory drugs (nsaids)
08/16/2007US20070190143 Disintegrating tablets comprising licarb azepine
08/16/2007US20070190140 Pharmaceutical Composition in the Form of a Gastric-Resident Tablet Containing an Active Principle